argenx SE盘前大跌，新药研究未能达到主、次要终点

智通财经2023-12-20

荷兰生物技术公司argenx SE表示，其皮下注射剂efgartigimod用于治疗成人寻常型天疱疮(PV)和落叶型天疱疮(PF)的3期ADDRESS研究未达到主要或次要终点。受此消息影响，截至发稿，argenx SE周三美股盘前大跌超23%。资料显示，天疱疮是一类罕见的严重威胁人类健康的自身免疫性皮肤黏膜大疱性疾病，患者皮肤或黏膜上会出现松弛性大疱，并且疱易破溃后呈现糜烂面。寻常型天疱疮和落叶型...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2392195395?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2023-12-20 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2392195395","market":"us","top_or_hot":-1,"title":"argenx SE盘前大跌，新药研究未能达到主、次要终点","media":"智通财经","content":"<div>\n<p>荷兰生物技术公司argenx SE表示，其皮下注射剂efgartigimod用于治疗成人寻常型天疱疮(PV)和落叶型天疱疮(PF)的3期ADDRESS研究未达到主要或次要终点。受此消息影响，截至发稿，argenx SE周三美股盘前大跌超23%。资料显示，天疱疮是一类罕见的严重威胁人类健康的自身免疫性皮肤黏膜大疱性疾病，患者皮肤或黏膜上会出现松弛性大疱，并且疱易破溃后呈现糜烂面。寻常型天疱疮和落叶型...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1043044.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>argenx SE盘前大跌，新药研究未能达到主、次要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nargenx SE盘前大跌，新药研究未能达到主、次要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-20 20:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1043044.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>荷兰生物技术公司argenx SE表示，其皮下注射剂efgartigimod用于治疗成人寻常型天疱疮(PV)和落叶型天疱疮(PF)的3期ADDRESS研究未达到主要或次要终点。受此消息影响，截至发稿，argenx SE周三美股盘前大跌超23%。资料显示，天疱疮是一类罕见的严重威胁人类健康的自身免疫性皮肤黏膜大疱性疾病，患者皮肤或黏膜上会出现松弛性大疱，并且疱易破溃后呈现糜烂面。寻常型天疱疮和落叶型...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1043044.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1043044.html","article_id":"2392195395","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2392195395","pubTimestamp":1703075430,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"argenx SE表示，它不会针对天疱疮进行进一步开发。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"argenx SE plummeted before the market, and new drug research failed to reach the primary and secondary endpoints","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/fa5afae750d3bba3ea922d712251ea2c","symbols_score_info":{"ARGX":1},"content_text":"荷兰生物技术公司argenx SE表示，其皮下注射剂efgartigimod用于治疗成人寻常型天疱疮(PV)和落叶型天疱疮(PF)的3期ADDRESS研究未达到主要或次要终点。受此消息影响，截至发稿，argenx SE周三美股盘前大跌超23%。资料显示，天疱疮是一类罕见的严重威胁人类健康的自身免疫性皮肤黏膜大疱性疾病，患者皮肤或黏膜上会出现松弛性大疱，并且疱易破溃后呈现糜烂面。寻常型天疱疮和落叶型天疱疮是天疱疮中最常见的类型。3期ADDRESS研究结果显示，使用最小剂量类固醇(CRmin)治疗的寻常型天疱疮或落叶型天疱疮患者达到完全缓解的主要终点的比例与使用皮下注射剂efgartigimod治疗的患者之间没有显著差异。argenx SE表示，它不会针对天疱疮进行进一步开发，并计划优先考虑皮下注射剂efgartigimod在其正在进行的严重自身免疫性适应症中的临床开发。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2392195395"}